



Press Release

MEDIAN Technologies Signs a €384K Contract with a San Francisco-area Biotech Company

MEDIAN Technologies will provide imaging services for a phase II study on lung cancer

SOPHIA ANTIPOLIS, France - January 09, 2014 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has signed a contract with a San Francisco-area based biotech company. The contract amount is €384,000 (eq. \$ 524,500).

MEDIAN Technologies will provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer. Within the framework of the study, imaging data will be acquired from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a “first patient in” forecasted May, 2014. MEDIAN will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.

“We are pleased to start 2014 supporting this important trial for a new, hypoxia-targeted therapy,” said Ciaran Cooper, Head of Business Development, Clinical Trials Imaging, North America. *“Adding this new biotech client demonstrates that our imaging services bring value not only to major pharmaceutical companies, but to top biotechnology companies as well.”*

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practices. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world’s largest CRO to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.mediantechologies.com



CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO

+33 4 92 90 65 82

fredrik.brag@mediantechnologies.com

Press

ALIZE RP

Caroline Carmagnol

+ 33 6 64 18 99 59

caroline@alizerp.com

Christian Berg

+ 33 1 70 22 53 86

christian@alizerp.com

Investors

ACTIFIN

Anaïs de Scitivaux

+ 33 1 56 88 11 14

adescitivaux@actifin.fr